10x Genomics, Inc. (TXG) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.01%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 16.01% | Share-based compensation / revenue. Period ending 2026-06-30. $98.74M ÷ $616.91M × 100 ≈ 16.01% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 616.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 98.74M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -88.38M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $616.91M | $98.74M | $-88.38M | (m) | (m) | 16.01% | (m) | (m) |
| 2026-03-31 | (m) | $638.78M | $100.68M | $-38.70M | (m) | (m) | 15.76% | (m) | (m) |
| 2025-12-31 | (m) | $642.82M | $109.12M | $-60.98M | (m) | (m) | 16.97% | (m) | (m) |
| 2025-09-30 | (m) | $641.81M | $116.44M | $-91.28M | (m) | (m) | 18.14% | (m) | (m) |
| 2025-06-30 | (m) | $644.47M | $124.76M | $-100.53M | (m) | (m) | 19.36% | (m) | (m) |
| 2025-03-31 | (m) | $624.66M | $135.70M | $-172.39M | (m) | (m) | 21.72% | (m) | (m) |
| 2024-12-31 | (m) | $610.78M | $140.75M | $-194.56M | (m) | (m) | 23.04% | (m) | (m) |
| 2024-09-30 | (m) | $629.74M | $147.13M | $-199.91M | (m) | (m) | 23.36% | (m) | (m) |
| 2024-06-30 | (m) | $631.73M | $153.77M | $-253.22M | (m) | (m) | 24.34% | (m) | (m) |
| 2024-03-31 | (m) | $625.45M | $160.98M | $-274.84M | $15.00K | (m) | 25.74% | -18322.60× | Reported |
| 2023-12-31 | (m) | $618.73M | $166.95M | $-265.33M | $33.00K | (m) | 26.98% | -8040.27× | Reported |
| 2023-09-30 | (m) | $590.98M | $169.01M | $-233.24M | $150.00K | (m) | 28.60% | -1554.91× | Reported |
| 2023-06-30 | (m) | $568.41M | $162.28M | $-178.44M | $263.00K | (m) | 28.55% | -678.47× | Reported |
| 2023-03-31 | (m) | $536.20M | $152.90M | $-178.20M | $367.00K | (m) | 28.52% | -485.55× | Reported |
| 2022-12-31 | (m) | $516.41M | $136.85M | $-167.94M | $476.00K | (m) | 26.50% | -352.82× | Reported |
| 2022-09-30 | (m) | $503.71M | $122.78M | $-160.68M | $568.00K | (m) | 24.37% | -282.88× | Reported |
| 2022-06-30 | (m) | $497.93M | $115.21M | $-136.56M | $673.00K | (m) | 23.14% | -202.91× | Reported |
| 2022-03-31 | (m) | $499.17M | $105.83M | $-83.77M | $773.00K | (m) | 21.20% | -108.37× | Reported |
| 2021-12-31 | (m) | $490.49M | $95.96M | $-52.25M | $866.00K | (m) | 19.56% | -60.34× | Reported |
| 2021-09-30 | (m) | $459.18M | $83.33M | $-446.01M | $966.00K | (m) | 18.15% | -461.70× | Reported |
| 2021-06-30 | (m) | $405.70M | $71.16M | $-495.38M | $1.14M | (m) | 17.54% | -433.03× | Reported |
| 2021-03-31 | (m) | $332.76M | $58.08M | $-524.47M | $1.24M | (m) | 17.46% | -422.62× | Reported |
| 2020-12-31 | (m) | $298.85M | $48.63M | $-534.14M | $1.68M | (m) | 16.27% | -317.56× | Reported |
| 2020-09-30 | (m) | $261.92M | $39.43M | $-132.64M | $2.36M | (m) | 15.06% | -56.27× | Reported |
| 2020-06-30 | (m) | $251.31M | $29.52M | $-76.48M | $2.67M | (m) | 11.75% | -28.67× | Reported |
| 2020-03-31 | (m) | $264.22M | $18.69M | $-47.42M | $3.06M | (m) | 7.07% | -15.51× | Reported |
| 2019-12-31 | (m) | $245.89M | $13.33M | $-30.57M | $3.08M | (m) | 5.42% | -9.93× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $196.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $172.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $146.31M | $2.66M | $-110.76M | $2.41M | (m) | 1.82% | -45.98× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $71.08M | $1.66M | $-18.38M | $811.00K | (m) | 2.34% | -22.66× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.